CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 123 enrolled
Drug / intervention
ganaxolonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00512317
NCT00512317Phase 2Completed

An Open-label Extension Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as add-on Therapy in Adult Patients With Epilepsy Consisting of Uncontrolled Partial-onset Seizures.

Marinus Pharmaceuticals·interventional·Posted Aug 7, 2007·Updated Jan 17, 2023

In Brief

A Phase 2 clinical trial evaluating ganaxolone for Epilepsies, Partial. Completed, enrolled 123 participants across 25 sites.

Detailed Summary

To allow open-label extension to patients who have completed Protocol 1042-0600.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 7, 2007
Enrollment StartJun 1, 2007
Primary CompletionDec 1, 2009
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.9 years ago

Interventions

ganaxolonedrug

liquid suspension dosed tid